Omzo vs Strut Health: Compounded Injections vs Oral GLP-1
The Omzo vs Strut Health comparison centers on two different telehealth approaches to GLP-1 therapy: Omzo emphasizes clinician-guided compounded injections including semaglutide and tirzepatide, while Strut Health specializes in oral semaglutide with guided consults. Early verdict: choose Omzo if you want clinician-reviewed compounded injectable options and shipping bundled in program fees; choose Strut Health if you want an oral-first program with daily lozenges and a lower monthly pathway for oral care.
Explore Omzo clinician-guided plans
How these providers differ at a glance
This comparison uses source details from each provider to focus on the most distinctive supported differences: medication form and specialization, pricing structure and starting costs, clinical model and prescribing notes, and regulatory status of compounded products.
1. Medication form and specialization
Omzo: Offers compounded semaglutide and tirzepatide as one weekly injection options as part of a clinician-guided program. Their platform connects users with licensed medical providers who may prescribe compounded medications or write prescriptions for branded products that the patient must fill separately.
Strut Health: Focuses on oral semaglutide lozenges and positions itself as an oral-specialized clinic. Their clinical team specializes in oral medication management and instructs lozenge use once daily for sublingual absorption when medically necessary.
2. Pricing and billing approach
Omzo: Lists semaglutide starting at $179 and tirzepatide starting at $279. The Omzo description notes medication costs are included in fees collected by Omzo and Omzo pays the pharmacies for compounded programs.
Strut Health: Promotes oral GLP-1 from $199 per month and highlights no hidden fees, free shipping, and cancel anytime for their oral options. The site also references a $99 item in captured landing page evidence but the primary monthly offer is from $199 per month.
3. Clinical model and eligibility
Omzo: Uses third party networks of U.S. licensed clinicians who determine eligibility and prescribe based on professional judgment. Omzo is not a medical practice and the online assessment does not create a doctor patient relationship. Providers make final determinations and eligibility, state availability, renewal terms and pharmacy details may change.
Strut Health: Requires medical necessity for compounded semaglutide and states oral semaglutide is only available for patients who fail or cannot use commercially available GLP-1 medications. Their model emphasizes guided consults and ongoing progress communication focused on oral therapy.
4. Regulatory and product notes
Both providers offer compounded medications and include regulatory notes that compounded medications are not FDA approved and are not reviewed by the FDA for safety, effectiveness or quality. Omzo explicitly states compounded drugs are not FDA approved and are prepared and shipped by a state licensed sterile compounding pharmacy. Strut Health documents that compounded semaglutide is prepared by a U.S. licensed compounding pharmacy pursuant to an individualized prescription.
Side by side: Key criteria
| Criteria | Omzo | Strut Health |
|---|---|---|
| Primary medication form | Compounded injectable semaglutide and tirzepatide (weekly) | Oral semaglutide lozenges (daily) |
| Starting price shown | Semaglutide starting at $179; tirzepatide starting at $279 | From $199 per month (oral plan) |
| Clinical model | Clinician-guided plans reviewed by licensed U.S. providers; third party clinician networks | Guided consults; specialization in oral medication management |
| Compounded medication status | Compounded medications not FDA approved; shipped by state licensed sterile compounding pharmacy | Compounded medications not FDA approved; prepared by U.S. licensed compounding pharmacy |
| Shipping and fees | Fast, discreet delivery; medication costs included in program fees for compounded options | No hidden fees noted; free shipping for oral options |
What each provider emphasizes
Omzo emphasizes clinician-guided GLP-1 care with injectable compounded semaglutide and tirzepatide and includes medication costs in program fees for compounded offerings. Strut Health emphasizes a streamlined oral-first program with daily lozenges, guided consults, and an oral specialization designed for patients needing oral options.
See Omzo injectable and tirzepatide options
View Strut Health oral semaglutide plans
Safety and expectations to confirm before enrolling
Both providers state compounded medications are not FDA approved and that eligibility, prescribing, state availability, and renewal terms are determined by licensed clinicians. Omzo notes the assessment on its website does not create a doctor patient relationship and providers make the final determination. Strut Health requires medical necessity for compounded semaglutide and limits oral semaglutide to patients who fail or cannot use commercially available GLP-1 medications.
Check Omzo eligibility and starting prices
Final verdict and quick recommendation
Omzo vs Strut Health comes down to injectable compounded options with clinician-reviewed programs versus an oral-first clinic that specializes in daily lozenge therapy. If you prioritize clinician-guided weekly injectable semaglutide or tirzepatide and a bundled medication fee model, Omzo aligns with those priorities. If you need or prefer oral semaglutide lozenges and a program built around oral medication management with monthly pricing, Strut Health is built for that use case.
Choose Omzo if…
Choose Omzo if you want clinician-guided access to compounded semaglutide or tirzepatide injections with medication costs included in program fees, and you accept that compounded medications are not FDA approved and that providers determine eligibility.
Choose Strut Health if…
Choose Strut Health if you are specifically seeking an oral semaglutide program with guided consults, daily sublingual lozenges, free shipping on oral options, and a monthly pricing pathway for oral therapy.